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Abstract
We analyzed the tissue distribution of apelin mRNA in rats by a quantitative reverse transcription-polymerase chain
reaction and that of immunoreactive apelin (ir-apelin) by an enzyme immunoassay (EIA) using a monoclonal antibody. The
expression levels of apelin mRNA and ir-apelin seemed to be consistent among tissues: they were highly expressed in the lung
and mammary gland. By the combination of gel filtration and EIA, we found that the molecular forms of apelin differ among
respective tissues: apelin molecules with sizes close to apelin-36 (long forms) were major components in the lung, testis, and
uterus, but both long and short (whose sizes were close to [6Glu65]apelin-13) forms were detected in the mammary gland. In
Scatchard analyses, the radioiodinated apelin-36 analogue bound to the receptor, APJ, with high affinity. In competitive
binding assays, apelin-36 and apelin-19 far more efficiently inhibited the binding of the labeled apelin-36 analogue with APJ
than [6Glu65]apelin-13. In analyses for the dissociation of apelin from APJ, unlabeled apelin-36 replaced more rapidly the
labeled apelin-36 analogue bound with APJ than [6Glu65]apelin-13. Our results demonstrate that the long and short forms
of apelin differently interact with APJ. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Apelin is a novel bioactive peptide originally iso-
lated as the endogenous ligand of the orphan G pro-
tein-coupled receptor (GPCR), APJ [1,2], by apply-
ing our strategy to identify ligands for orphan
GPCRs [3,4]. Apelin speci¢cally induces the promo-
tion of extracellular acidi¢cation and inhibition of
cAMP production in Chinese hamster ovary (CHO)
cells transfected with APJ cDNA (CHO-A10) but
not control CHO cells. Apelin is produced through
processing from the C-terminal portion in the pre-
proprotein consisting of 77 amino acid residues.
Although apelin with 36 amino acid length (apelin-
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36) was originally isolated from bovine stomach tis-
sue extracts, synthetic C-terminal apelin peptides
with various sizes have been found to retain the ag-
onistic activities on CHO-A10 cells. Apelin mRNA is
highly expressed in the mammary gland during preg-
nancy and lactation and apelin is abundantly se-
creted in milk, especially in colostrum [5]. We have
found that endogenous apelin exists in multiple mo-
lecular forms. Apelin molecules with both sizes cor-
responding to the long (apelin-36) and short
([6Glu65]apelin-13) forms have been detected in
the bovine colostrum [6].
Although the main physiological functions of ape-
lin and APJ have not been clari¢ed yet, we have
found that apelin partially suppresses cytokine pro-
duction from mouse spleen cells in in vitro culture [5]
and that apelin shows chemotactic activity on CHO-
A10 cells [6]. It has been reported that the adminis-
tration of apelin to rats lowers blood pressure and
increases drinking behavior [7]. In addition, APJ is
reportedly able to function as one of the co-receptors
together with CD4 in the process of human immu-
node¢ciency virus (HIV) infection [8^11], although
CXCR4 and CCR5 are thought to function as
main co-receptors [12]. APJ does not show overall
high homology with chemokine receptors, such as
CCR5, CCR3, and CXCR4, but it has sequence sim-
ilarity to these chemokine receptors in the N-termi-
nal region which is con¢rmed to be very important
for the interaction with HIV [10].
In this paper, we analyzed the precise tissue distri-
bution of apelin mRNA by reverse transcription-
polymerase chain reaction (RT-PCR) and that of rat
immunoreactive apelin (ir-apelin) in various tissues by
an enzyme immunoassay (EIA) using a speci¢c anti-
apelin monoclonal antibody (mAb). We subsequently
analyzed molecular heterogeneity of endogenous ape-
lin by gel ¢ltration chromatography and EIA. Finally
we demonstrate here that the long (apelin-36) and
short ([6Glu65]apelin-13) forms of apelin have quite
di¡erent properties in the binding with APJ.
2. Materials and methods
2.1. Animals
Adult male or female Wistar rats (SLC Japan) and
female BALB/c mice (SLC Japan) were housed under
controlled temperature and lighting conditions (lights
on from 08.00 to 20.00 h) and supplied with water
and food ad libitum. All experiments using rats and
mice were conducted according to a guideline of the
internal animal care and use committee.
2.2. Quantitative analyses for rat apelin mRNA by
RT-PCR
Poly(A)RNAs were prepared from the tissues of
8-week-old male or female Wistar rats using an
mRNA Puri¢cation Kit (Amersham Pharmacia Bio-
tech). Complement DNAs were synthesized from
poly(A)RNAs (160 ng) treated with deoxyribonu-
clease I (ampli¢cation grade, Gibco BRL) in the
presence of AMV reverse transcriptase XL (Life Sci-
ences) at 10 units in 40 Wl of the bu¡er provided by
the manufacturer, with 2.5 WM of random 9-mer
nucleotides (Takara Shuzo) and 1 mM of dNTPs
at 42‡C for 30 min. According to the method de-
tailed previously [6], we quanti¢ed rat apelin
mRNA by means of a Prism 7700 Sequence Detector
(Applied Biosystems) with a primer set (5P-GGCTA-
GAAGAAGGCAACATGC-3P, 5P-CCGCTGTCTG-
CGAAATTTC-3P) and a hybridization probe labeled
with £uorescent dyes (5P(FAM)-TGGTGAAGCC-
CAGAACTTCGAGGA-(TAMRA)3P). Rat glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA expression was also measured as an internal
control using Rodent GAPDH Control Reagents
(Applied Biosystems) according to the manufactur-
er’s instruction.
2.3. Synthesis of apelin peptides
Apelin-36 (i.e., LVQPRGPRSGPGPWQGGRR-
KFRRQRPRLSHKGPMPF), [Nle75,Tyr77]apelin-36
(i.e., LVQPRGPRSGPGPWQGGRRKFRRQRPR-
LSHKGPXPY; X means norleucine), apelin-19
(i.e., RRKFRRQRPRLSHKGPMPF), [Cys61]-
apelin-17 (i.e., CFRRQRPRLSHKGPMPF), apelin-
15 (i.e., RRQRPRLSHKGPMPF), [6Glu65]apelin-
13 (i.e., 6QRPRLSHKGPMPF), [6Glu65,Nle75,
Tyr77]apelin-13 (i.e., 6QRPRLSHKGPXPY; X
means norleucine), [6Glu65]apelin-13-(65^76)-pep-
tide (i.e., 6QRPRLSHKGPMP), [6Glu65]apelin-
13-(65^75)-peptide (i.e., 6QRPRLSHKGPM),
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[6Glu65]apelin-13-(65^74)-peptide (i.e., 6QRPR-
LSHKGP), [6Glu65]apelin-13-(65^73)-peptide (i.e.,
6QRPRLSHKG), apelin-12 (i.e., RPRLSHKGP-
MPF), and apelin-10 (i.e., RLSHKGPMPF) were
synthesized using an automatic peptide synthesizer
(Model 430, Applied Biosystems) as described previ-
ously [6].
2.4. Preparation of anti-apelin mAb
[6Glu65]Apelin-13 at 2 mg was conjugated with a
carrier protein, cationized bovine serum albumin
(Pierce), at 2 mg in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride
(Pierce) and N-hydroxysulfosuccinimide (Pierce) in
a bu¡er containing 50 mM 2-morpholinoethanesul-
fonic acid, monohydrate (Dojindo) at pH 6, and 250
mM NaCl through incubation at 4‡C for 4 h. The
resultant conjugates were puri¢ed with a Kwik Sep
Dextran Desalting column (Pierce) according to the
manufacturer’s instruction. In order to raise anti-
apelin antibodies, the puri¢ed conjugate at 80 Wg
admixed with complete or incomplete Freund’s adju-
vant (Difco) was subcutaneously injected into BALB/
c mice (female, 8 weeks old) twice at 3 week inter-
vals. One week after the last subcutaneous injection,
160 Wg of the conjugate was intravenously injected
into each mouse. Four days after the intravenous
injection, spleen cells obtained from each immunized
mouse were fused with mouse myeloma cells (P3-
X63Ag8-U1) using polyethylene glycol 1500 (Boehr-
inger) according to the manufacturer’s instruction. A
hybridoma cell line, 4G5, thus obtained was cultured
in an INTEGRA CL-1000 system (Integra Bioscien-
ces). After culture for 10 days, anti-apelin mAb was
puri¢ed from the resultant culture medium with a
HiTrap rProtein A column (Amersham Pharmacia
Biotech). The isotype of the puri¢ed antibody was
determined with a Mouse mAb isotyping kit (Amer-
sham Pharmacia Biotech).
2.5. Construction of EIA
[Cys61]Apelin-17 at 0.67 mg was mixed with 6 mg
of horseradish peroxidase (HRP; Boehringer) which
was previously maleimidated with N-(Q-maleidobu-
tyryloxy)succinimide (Dojindo), and the mixture
was incubated for 16 h at 4‡C. The resultant HRP-
conjugated [Cys61]apelin-17 (HRP-apelin) was puri-
¢ed by gel ¢ltration on Superose 12 HR 10/30 col-
umn (Amersham Pharmacia Biotech), and then used
as a tracer. Anti-mouse IgGAM (Cappel) dissolved
at 15 Wg/ml in 0.1 M carbonate bu¡er at pH 9.5 was
added to 96-well microplates (Nunc), and then incu-
bated at 4‡C overnight. After blocking the substrate
with Block Ace (Dainippon Pharmaceutical), the
anti-mouse IgG-coated microplates were used for fol-
lowing EIA. The puri¢ed anti-apelin mAb (50 Wl)
appropriately diluted with phosphate-bu¡ered saline
(PBS) containing 2 mM EDTA, 0.4% bovine serum
albumin (BSA), 0.1 M NaCl, and 0.1% micro-O-pro-
tect (Boehringer) was added to each well of the anti-
mouse IgG-coated microplates. Each sample dis-
solved in the same bu¡er (50 Wl) was then added to
the well. After incubation at 4‡C for 16 h, HRP-
apelin was added to each well and incubated at
4‡C for 8 h. The microplates were washed with
PBS containing 0.1% Tween 20 (Sigma), and then
the HRP activity retained in each well was measured
with a TMB microwell peroxidase system (Kirke-
gaardpPerry Labs). We quanti¢ed ir-apelin on the
basis of a dose-response curve using human apelin-
36 as a reference.
2.6. Preparation of tissue extracts
Tissues were collected from male or female Wistar
rats (8 weeks old) immediately after decapitation,
and then frozen at 380‡C until used. The mammary
glands were collected from female Wistar rats within
1 day after parturition. Whole blood obtained from
each rat was collected in a chilled tube containing
300 000 IU/ml of aprotinin and 10 mM of EDTA,
and then centrifuged at 1500Ug for 20 min at 4‡C to
prepare plasma [13]. Each tissue (0.2^2 g) or plasma
was boiled in water for 15 min, and then homoge-
nized in 1 M acetic acid with a Polytron homogeniz-
er. After centrifugation, the resultant supernatant
was subjected to a Sep-Pak Vac C18 column
(Waters), and then eluted with stepwise increments
of 10, 30, and 50% acetonitrile containing 0.1% tri-
£uoroacetic acid (TFA). Fractions eluted with 30%
acetonitrile were diluted with 2 vols. of 20 mM
CH3COONH4 at pH 6.4, and then applied to a Hi-
Trap CM-Sepharose FF 5 ml column (Amersham
Pharmacia Biotech). Elution from CM-Sepharose
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was performed with stepwise increments of 200 and
1000 mM CH3COONH4 at pH 6.4 containing 10%
acetonitrile. Fractions eluted with 1000 mM
CH3COONH4 were desalted with a Sep-Pak plus
C18 column, dried, and then used as samples for
the EIA.
2.7. Gel ¢ltration
The tissue extracts (i.e., fractions eluted with 1000
mM CH3COONH4 in CM-Sepharose column chro-
matography) prepared from the lung, testis, uterus,
and mammary gland were applied to gel ¢ltration
chromatography using a Superdex Peptide PC 3.2/
30 column in a SMART system (Amersham Pharma-
cia Biotech). Elution was performed in 40% acetoni-
trile containing 0.1% TFA at a £ow rate of 25 Wl/
min.
2.8. Receptor-binding assays
Apelin analogues, [6Glu65,Nle75,Tyr77]apelin-13
and [Nle75,Tyr77]apelin-36, were labeled respectively
with Na125I (IMS-30, Amersham Pharmacia Biotech)
by the method using lactoperoxidase (Sigma) as de-
scribed elsewhere [14]. After the reaction, labeled and
unlabeled peptides were separated through a reverse
phase-high performance liquid chromatography us-
ing a TSKgel ODS-80 TM CTR (Tosoh). Aliquots
of the labeled peptide were stored at 330‡C until
used. The membrane fractions of CHO-A10 cells pre-
pared by the method as described previously [6] were
incubated with [125I][6Glu65,Nle75,Tyr77]apelin-13
or [125I][Nle75,Tyr77]apelin-36 in 100 Wl of the binding
bu¡er containing 0.1% BSA in 96-well microplates
(SEROCLUSTER, Corning Costar) at room temper-
ature. In the binding assay using [125I][Nle75,Tyr77]-
apelin-36, 1 WM of poly-L-lysine (Wako) was also
added to prevent nonspeci¢c binding. In order to
determine the amounts of nonspeci¢c binding, 1 WM
of unlabeled apelin analogues was simultaneously
added to the wells. After incubation, bound and
free radioactivities were separated through rapid ¢l-
tration using the glass ¢ber ¢lter units (GF/C, Pack-
ard) of a 96-well cell harvester (Packard). The ¢lter
units were completely dried, and the Microcinti O
(Packard) was added to each well. The radioactivity
of each well was counted with a TopCount liquid
scintillation counter (Packard). The dissociation con-
stant (Kd) and the number of binding sites (Bmax) at
90 min of incubation were determined by the Scatch-
ard method [15]. In time course analyses for the dis-
sociation of apelin, radiolabeled apelin analogues
(0.1 nM at ¢nal concentration) were incubated with
the membrane fraction of CHO-A10 cells, and then
radioactivities bound to the membrane were deter-
mined every 30 min for 4 h. Dissociation of the la-
beled apelin analogues was examined by the addition
of 0.1 WM of unlabeled [6Glu65]apelin-13 or apelin-
36, respectively, at 90 min after the incubation.
2.9. Assay for cAMP production-inhibitory activity
The inhibitory activity of apelin to forskolin-in-
duced cAMP production in CHO-A10 cells was mea-
sured as described previously [5].
3. Results
3.1. Construction of EIA to detect apelin
We established a hybridoma cell line, 4G5, secret-
ing anti-apelin mAb, by fusing myeloma cells to
spleen cells obtained from mouse immunized with
apelin. Anti-apelin mAb produced by 4G5 consisted
of IgG1 heavy chains and U light chains. By utilizing
this mAb, we constructed an EIA to detect apelin.
We detected apelin by the competition of samples
against HRP-apelin which could be recognized by
the anti-apelin mAb. In order to determine which
epitope was recognized by the mAb, we examined
its reactivity against various apelin peptides in the
EIA. As shown in Fig. 1, apelin-36, apelin-15, and
[6Glu65]apelin-13 were detectable by this EIA,
though apelin-36 was somewhat more e⁄ciently de-
tected than apelin-15 and [6Glu65]apelin-13. In ac-
cordance with the deletion of the C-terminal amino
acid residues in [6Glu65]apelin-13, apelin peptides
gradually lost the reactivity to the mAb, though the
deletion of the C-terminal Phe77 little a¡ected the
reactivity. The rank order of the reactivity was as
follows: [6Glu65]apelin-13 = (65^76)-peptides (65^
75)-peptides (65^74)-peptides (65^73)-peptide. The
deletion of the N-terminal amino acid residues in
[6Glu65]apelin-13 more drastically attenuated the
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reactivity to the mAb. The rank order of the reac-
tivity was as follows: [6Glu65]apelin-13s apelin-
12s apelin-10. These results suggested that the
mAb essentially recognized the epitope correspond-
ing to (65^76)-peptide in apelin.
We subsequently examined the speci¢city of the
EIA. As shown in Fig. 2, we could detect synthetic
human apelin-36 at at least 4 fmol/well by EIA.
However, we could not detect the other 12 known
Fig. 2. Speci¢c detection of apelin by EIA. The indicated
amounts of synthetic human apelin-36 (b) were tested in the
EIA under the same conditions as in Fig. 1. Other bioactive
peptides (R) including prolactin-releasing peptide-31, Arg-vaso-
pressin, corticotropin-releasing hormone, vasoactive intestinal
peptide, substance P, angiotensin II, oxytocin, pituitary adenyl-
ate cyclase-activating peptide, neurotensin, growth hormone-re-
leasing hormone, thyrotropin-releasing hormone and gonadotro-
pin-releasing hormone did not inhibit the binding of HRP-
apelin to the mAb.
Fig. 1. Reactivity of anti-apelin mAb with apelin-related pep-
tides. The puri¢ed anti-apelin mAb (4G5) was added to each
well of the anti-mouse IgG-coated microplates. Samples (human
apelin-36 (b), apelin-15 (8), [6Glu65]apelin-13 (F), [6Glu65]-
apelin-13-(65^76)-peptide (E), [6Glu65]apelin-13-(65^75)peptide
(7), [6Glu65]apelin-13-(65^74)peptide (a), [6Glu65]apelin-13-
(65^73)peptide (O), apelin-12 (R), and apelin-10 (S)) were
then added to the well, respectively. After incubation for 16 h,
HRP-apelin was added to each well and incubated for 8 h.
After the plates were washed, the HRP activity retained in each
well was measured. Data are expressed as means in duplicate
assays. B, HRP activity detected in the presence of a sample;
Bo, HRP activity detected in the absence of a sample.
Fig. 3. Tissue distribution of apelin in rats. (A) Distribution of
apelin mRNA. Poly(A)RNA preparations obtained from the
indicated rat tissues were subjected to quantitative RT-PCR
analyses using a Prism 7700 Sequence Detector. Poly(A)RNA
of the mammary gland was prepared from female rats within
1 day after parturition. (B) Distribution of ir-apelin. The con-
tents of ir-apelin in the extracts prepared from the indicated tis-
sues were determined by EIA. A calibration curve to quantify
the contents of ir-apelin was obtained using synthetic human
apelin-36. Data represent means þ S.E.M. of multiple assays.
n = 4 or 5, except for the pituitary gland and adrenal gland
which were pooled from 20 and 10 rats, respectively.
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peptides including angiotensin II even at 50 pmol/
well.
3.2. Tissue distribution of apelin mRNA in rats
We quantitatively analyzed the precise distribution
of apelin mRNA in rat tissues by RT-PCR. As
shown in Fig. 3A, we detected apelin mRNA in al-
most all of the tissues tested, although the quantity
of apelin mRNA varied considerably among them.
We detected the highest level of apelin mRNA in the
mammary gland of rats after parturition. A very high
level of apelin mRNA was detected in the lung. In
the central nervous system, apelin mRNA was de-
tected in the multiple areas in relatively high quan-
tity. Moderate levels of apelin mRNA were detected
in the heart, adipose, testis, and ovary. We ampli¢ed
the same cDNA preparations with a set of primers
corresponding to GAPDH cDNA as a control.
The levels of ampli¢ed GAPDH cDNA were almost
consistent among the tissues within the range of
0.7U105^9.1U105 copies/ng poly(A)RNA, except
for the pituitary, heart, and mammary gland
(1.1U106^2.2U106 copies/ng poly(A)RNA) and the
skeletal muscle (4.6U106 copies/ng poly(A)RNA).
3.3. Tissue distribution of ir-apelin in rats
We measured the contents of ir-apelin in extracts
prepared from rat by EIA. As shown in Fig. 3B, the
highest concentration of ir-apelin (15 pmol/g tissue)
was detected in the mammary gland of rats after
parturition. A high concentration of ir-apelin (5.2
pmol/g tissue) was detected in the lung. In these tis-
sues, high levels of apelin mRNA expression were
also detected as described above. In the other tissues,
the contents of ir-apelin were not so high, although
signi¢cant levels of ir-apelin were detected in all tis-
sues examined. In the plasma samples prepared from
male and female rats, the ir-apelin concentrations
were lower (i.e., 0.023 and 0.052 pmol/ml, respec-
tively) than those in the other tissues.
3.4. Heterogeneity of endogenous apelin molecules
Molecular heterogeneity of ir-apelin among rat tis-
sues was analyzed by gel ¢ltration chromatography
in combination with EIA. As shown in Fig. 4, in the
lung, testis, and uterus, ir-apelin was mainly eluted at
the position corresponding to apelin-36. However, in
the mammary gland, ir-apelin was eluted as two
peaks at a position slightly greater than apelin-36
and at that of around [6Glu65]apelin-13.
3.5. Properties of apelin-36 in binding to APJ
In order to analyze the receptor-binding properties
of apelin-36, we prepared [125I][Nle75,Tyr77]apelin-36.
We used [Nle75,Tyr77]apelin-36 in the radioiodination
because of the following reasons. As there was no
tyrosine residue for radioiodination using lactoper-
oxidase in the sequence of apelin-36, we substituted
Phe77 with Tyr77. [Nle75,Tyr77]Apelin-36 was almost
equivalently potent to apelin-36 in the agonistic ac-
tivity in the cAMP production-inhibitory assays
(data not shown). In order to prevent possible oxi-
dization at Met75 during the labeling reactions, we
Fig. 4. Gel ¢ltration of tissue extracts. Extracts which were pre-
pared from the indicated tissues and partially puri¢ed were sub-
jected to gel ¢ltration chromatography. Ir-apelin contained in
each fraction was quanti¢ed by EIA. Arrows indicate the posi-
tions of human apelin-36 (a) and [6Glu65]apelin-13 (b) eluted
in the same chromatography.
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substituted this residue with Nle (norleucine), be-
cause its oxidation was found to a¡ect the agonistic
activity of apelin-36 (data not shown). The substitu-
tion of Met75 to Nle75 did not reduce the agonistic
activity. We con¢rmed that the agonistic activity of
[Nle75,Tyr77]apelin-36 remained after iodination
(data not shown).
Scatchard plot analysis using the labeled apelin-36
analogue indicated that CHO-A10 cells expressed a
single class of high a⁄nity binding sites with a Kd of
6.3 pM and a Bmax of 7.4 pmol/mg protein (Fig. 5).
In competitive binding assays, unlabeled apelin-36
and apelin-19 e⁄ciently inhibited the binding of the
labeled apelin-36 analogue with APJ (Table 1). How-
ever, [6Glu65]apelin-13 little inhibited this binding.
In the activity to inhibit cAMP production in CHO-
A10 cells, [6Glu65]apelin-13 was slightly more po-
tent than apelin-36 and apelin-19 (Table 1).
In our previous study, it has been suggested that
apelin-36 more hardly dissociates from APJ than
[6Glu65]apelin-13 [6]. In order to examine directly
this presumption, we examined the dissociation of
radiolabeled [6Glu65]apelin-13 and apelin-36 ana-
Fig. 6. The time course of association and dissociation of radio-
labeled apelin analogues binding to APJ. The membrane prepa-
rations of CHO-A10 cells were incubated with 0.1 nM of
[125I][6Glu65,Nle75,Tyr77]apelin-13 (A) and [125I][Nle75,Tyr77]-
apelin-36 (B) at room temperature. Radioactivities (b) bound
to the membrane were measured at the indicated incubation
times. Radioactivities bound to the membrane after the addition
of 0.1 WM of [6Glu65]apelin-13 (O) or apelin-36 (F) at 90 min
of incubation (arrow) were also measured. The amounts of
nonspeci¢c binding were estimated by adding 1 WM of unla-
beled apelin analogues to the reaction (a). Data represent
means þ S.E.M. of triplicate assays.
Table 1
Comparison of apelin peptides in receptor-binding and cAMP
production-inhibitory assays
Peptide Receptor-binding assaya cAMP assayb
IC50 (nM) EC50 (nM)
Apelin-36 5.4 þ 0.06 0.52 þ 0.09
Apelin-19 8.0 þ 0.89 0.35 þ 0.03
[6Glu65]apelin-13 s 100 0.17 þ 0.02
aThe binding of [125I][Nle75,Tyr77]apelin-36 (100 pM) to the
membrane preparation of CHO-A10 cells was examined in the
presence of the indicated peptides. The bound and free ligands
were separated after incubation for 90 min at room tempera-
ture. Data represent means þ S.E.M. of triplicate assays.
bThe e¡ects of the indicated peptides on cAMP production in
CHO-A10 cells were examined in the presence of 0.2 mM 3-iso-
butyl-1-methylxanthine and 1 WM forskolin. Data represent
means þ S.E.M. of triplicate assays.
Fig. 5. Scatchard analysis for binding of radiolabeled apelin-36
with APJ. The membrane preparations of CHO-A10 cells were
incubated with increasing concentrations of [125I][Nle75,Tyr77]-
apelin-36 at room temperature. The bound and free ligands
were separated at the time when the binding of [125I][Nle75,
Tyr77]apelin-36 reached equilibrium (90 min). The amounts of
nonspeci¢c binding were estimated by adding 1 WM of unla-
beled [Nle75,Tyr77]apelin-36 to the reaction. Data are plotted as
bound (B, pmol mg31) versus the bound/free (B/F, pmol mg31
nM31) radiolabeled ligand. Data represent means þ S.E.M. of
triplicate assays. Standard error bars are invisible because they
lie inside the symbols.
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logues from APJ. As shown in Fig. 6A, the binding
of the labeled [6Glu65]apelin-13 analogue to the
CHO-A10 cell membrane was saturated within 30
min after starting the incubation, and the labeled
analogue bound to the membrane was e⁄ciently dis-
sociated by the addition of unlabeled [6Glu65]-
apelin-13 and apelin-36 at 90 min after the incuba-
tion. There were no apparent di¡erences in the ki-
netics of its dissociation induced by unlabeled
[6Glu65]apelin-13 and apelin-36. On the other
hand, the binding of the labeled apelin-36 analogue
to the membrane was more e⁄ciently dissociated by
the addition of unlabeled apelin-36 than [6Glu65]-
apelin-13 (Fig. 6B), indicating that apelin-36 more
hardly dissociates from APJ than [6Glu65]apelin-13.
4. Discussion
In the present study, we constructed a speci¢c EIA
for apelin with a minimum detectable level of 4 fmol/
well. The contents of ir-apelin in rat tissues (e.g.,
whole brain, heart, lung and adipose) were well con-
sistent with those of bioactive apelin measured on the
basis of the inhibitory activities on cAMP production
in CHO-A10 cells [5]. These results indicate that this
EIA detects mainly bioactive apelin.
By the analyses for apelin mRNA and ir-apelin,
we demonstrated that apelin was abundantly pro-
duced in the lung and mammary gland in rats. These
results are consistent with our previous observation
that stimulatory activities on CHO-A10 cells are
abundantly detectable in the lung and mammary
gland [5]. APJ mRNA has been found to be highly
expressed in the lung in rats [6]. Taken together with
the results in this study, it is suggested that apelin is
produced in the lung and functions in the vicinity of
the tissue. The highest levels of apelin mRNA and ir-
apelin were detected in the mammary gland in rats
after parturition. These results are consistent with
our previous observation that apelin is abundantly
secreted in bovine colostrum and milk [5]. In contrast
to the case of the lung, the expression of APJ mRNA
was at a low level in the mammary gland in the
extent that we examined [6]. It must be elucidated
in future studies whether apelin plays an important
role in the mammary gland.
Of interest, apelin concentration in plasma was
considerably lower than those in other tissues. It
has been recently reported that APJ is abundantly
expressed in the neurons and oligodendrocytes in
human, and mediates intracellular signals by apelin
[16]. We therefore consider that apelin would not act
as a circulating hormone and function in paracrine
such as a neuromodulator/neurotransmitter. In addi-
tion, we con¢rmed that apelin concentration in plas-
ma was not increased even during pregnancy and
lactation in rats (data not shown), suggesting that
apelin produced in the mammary gland is not deliv-
ered to other tissues in circulation. In the previous
study, moderate levels of APJ mRNA were detected
in the stomach and intestine in neonatal rats [6]. We
therefore speculate that apelin secreted into colos-
trum and milk might act on neonates through oral
intake. Although the contents were lower when com-
pared with the lung and mammary gland, ir-apelin
was detected in a variety of tissues. We have reported
that APJ mRNA is expressed in a variety of tissues
including the lung, heart, costal cartilage, placenta,
spinal cord, ovary, adipose, and thyroid gland in rats
when analyzed by RT-PCR [6]. In situ hybridization
has shown that APJ mRNA is expressed in the cen-
tral nervous system and peripheral tissues in rats [17].
These results suggest that apelin functions widely in
various tissues. It has been reported that APJ mRNA
is more highly expressed in neonates than in adults in
rats [2,6]. We observed that apelin mRNA was also
highly expressed in rat neonatal tissues including the
lung (data not shown). In addition, we have found
that apelin shows chemotactic activity on CHO-A10
cells [6]. We therefore speculate that apelin and APJ
are related to the regulation of morphogenesis in the
development of some tissues including the lung in
rats.
By analyzing the molecular forms of endogenous
apelin, we found that the large forms of apelin with
sizes close to apelin-36 were major constituents in
ordinary tissues including the lung. However, the
molecular forms of apelin produced in the rat mam-
mary gland appeared to be considerably heterogene-
ous; in addition to the large forms, small forms with
sizes close to [6Glu65]apelin-13 were detected. These
results well agree with our previous observation that
bovine colostrum and milk contain both large and
short forms of apelin [6]. Although it is unclear why
apelin produced in the mammary gland is so hetero-
BBAMCR 14725 13-4-01
Y. Kawamata et al. / Biochimica et Biophysica Acta 1538 (2001) 162^171 169
geneous, we have found that there are di¡erences in
some biological activities between apelin-36 and
[6Glu65]apelin-13 [5,6].
In Scatchard analysis, we found that a radiola-
beled apelin-36 analogue bound to APJ with a very
high a⁄nity (i.e., Kd of 6.3 pM). In our previous
study, the Kd value of a radiolabeled [6Glu65]-
apelin-13 analogue bound to APJ has been estimated
to be 22.3 pM [6]. Our results indicate that apelin-36
binds to APJ with higher a⁄nity than [6Glu65]-
apelin-13. In the competitive binding assays, unla-
beled apelin-36 and apelin-19 e⁄ciently inhibited
the binding of the radiolabeled apelin-36 analogue
to APJ. However, [6Glu65]apelin-13 did not. The
basic amino acid-rich N-terminal sequence of ape-
lin-19 (i.e., RRKFRR) thus appeared to be critical
in the e⁄cient inhibition of this binding. Besides, in
the time course study, the saturated binding of the
radiolabeled apelin-36 to APJ was e⁄ciently replaced
by unlabeled apelin-36 but not by [6Glu65]apelin-
13. We have reported that when CHO-A10 cells were
transiently exposed to apelin and their extracellular
acidi¢cation was analyzed by a Cytosensor, the stim-
ulation of apelin-36 was long lasting whereas that of
[6Glu65]apelin-13 was temporary [6]. These results
suggest that apelin-36 bound to APJ is harder to
dissociate from APJ than [6Glu65]apelin-13.
As we have reported, [6Glu65]apelin-13 shows
somewhat greater activity than apelin-36 in analyses
for dose responses in the suppression of cAMP pro-
duction, promotion of acidi¢cation rates, and che-
motaxis for CHO-A10 cells [5,6]. We think that these
di¡erences between apelin-36 and [6Glu65]apelin-13
might be related to the association with APJ. In this
study, we could not ¢nd a signi¢cant di¡erence in the
kinetics of the association of the radiolabeled
[6Glu65]apelin-13 and apelin-36 analogues with
APJ. More precise analyses will be required to clarify
their di¡erences in the association with APJ.
It has been reported that APJ could function as
one of the co-receptors together with CD4 in the
process of HIV infection in cells [8^11]. We and an-
other group recently reported that apelin inhibits
HIV infection in cells co-expressing CD4 and APJ,
and the inhibitory activity of apelin on the infection
is greater in apelin-36 than in [6Glu65]apelin-13
[18,19]. The inhibitory activities of apelin molecules
against HIV infection seem to be correlated with the
dissociation rather than the association with APJ.
Endogenous apelin has multiple molecular forms
and they di¡erently interact with the receptor. This
appears to be a unique character of apelin among
bioactive peptides. We believe that studies on apelin
will give insight into the unknown aspects of bioac-
tive peptides.
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